Has Bassem El-Nabbout received payments from drug or device companies?

Yes. Drug and device makers reported $317,772 in general payments to Bassem El-Nabbout across 917 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bassem El-Nabbout did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bassem El-Nabbout come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bassem El-Nabbout

Neurology with Special Qualifications in Child Neurology · Wichita, KSNPI 1558442210

Payments from drug & device makers

$317,772in general payments, 2019–2025

Across 917 payments — averaging $346.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Teva Pharmaceuticals USA, Inc.$259K
Eli Lilly$38K
Eisai Inc.$9K
UCB, Inc.$2K
Supernus Pharmaceuticals, Inc.$1K
Jazz Pharmaceuticals Inc.$1K
plus $6K from 41 others

$2in research payments, 2019–2025

Across 1 payment — averaging $1.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$2

What the payments were for

Food & beverage$11,44397%
Education$3243%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Teva Pharmaceuticals USA, Inc.	270	$259,283
Eli Lilly	3	$37,915
Eisai Inc.	27	$9,305
UCB, Inc.	139	$2,348
Supernus Pharmaceuticals, Inc.	104	$1,377
Jazz Pharmaceuticals Inc.	54	$1,317
AbbVie(2 entities)	56	$1,109
Neurelis, Inc.	41	$801
Sunovion Pharmaceuticals Inc.	29	$428
SK Life Science, Inc.	17	$368
Argenx US, Inc.	13	$343
Biogen	14	$340
AstraZeneca	13	$287
Sumitomo Pharma America, Inc.	15	$251
Immedica Pharma US, Inc.	8	$205
Novartis	10	$196
Catalyst Pharmaceuticals, Inc.	7	$174
Greenwich Biosciences, Inc.	8	$165
Acadia Pharmaceuticals Inc	8	$161
Amneal Pharmaceuticals LLC	8	$138
Lilly USA, LLC	8	$112
Ipsen Biopharmaceuticals, Inc	5	$102
Tris Pharma Inc	5	$92
Aucta Pharmaceuticals, Inc.	4	$90
Livanova USA, Inc.	3	$77
Cranial Technologies, Inc	5	$75
Aquestive Therapeutics, Inc.	4	$70
Philips North America LLC	3	$70
Zogenix Inc.	4	$67
NS Pharma, Inc.	3	$62
Sarepta Therapeutics, Inc.	2	$43
Mallinckrodt Enterprises LLC	2	$42
Azurity Pharmaceuticals, Inc.	2	$38
Travere Therapeutics, Inc.	7	$36
Genentech USA, Inc.	2	$36
Lundbeck LLC	2	$33
EMD Serono, Inc.	2	$29
Upsher-smith Laboratories LLC	1	$26
Pyros Pharmaceuticals, Inc.	1	$21
Ironshore Pharmaceuticals Inc.	1	$21
ANI Pharmaceuticals, Inc.	1	$20
Merz Pharmaceuticals, LLC	1	$19
Metacel Pharmaceuticals LLC	1	$18
Mallinckrodt Hospital Products Inc.	1	$17
Aprecia Pharmaceuticals, LLC	1	$15
Adlon Therapeutics L.p.	1	$15
GE HealthCare	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

BOTOX$125
SPINRAZA$122
QELBREE$122
VYVGART$100

How this compares

Too few neurology with special qualifications in child neurology providers in Kansasto place this figure against a meaningful peer group, so we don't.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Clonazepam	24	$85

Paid to pharmacies, not to this prescriber.

Other neurology with special qualifications in child neurology in Wichita

Subhash ShahWichita$2K
Aruna Deepthi Markonda PatnaikWichita$1K
Jean-Baptiste le PichonTopeka$815K
Yu Tze NgOverland Park$377K
Britton ZuccarelliSalina$314K
Gina JonesTopeka$177K

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →